We are testing a new medication for individuals with relapsed or refractory multiple myeloma or previously treated AL amyloidosis. The goal is to see how safe and effective this treatment is in humans.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed or Refractory Multiple Myeloma is a type of blood cancer that occurs when the disease returns after treatment or does not respond to treatment. It affects plasma cells in the bone marrow, leading to various complications.
Previously Treated AL Amyloidosis is a rare disease caused by the buildup of amyloid proteins in organs and tissues, often following treatment for the condition. It can lead to serious health issues depending on the organs affected.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
